Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program

BACKGROUND: Onartuzumab, a recombinant humanized monovalent monoclonal antibody directed against MET, the receptor for the hepatocyte growth factor, has been investigated for the treatment of solid tumors. This publication describes the safety profile of onartuzumab in patients with solid tumors usi...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:PLoS One
Hoofdauteurs: Morley, Roland, Cardenas, Alison, Hawkins, Peter, Suzuki, Yasuyo, Paton, Virginia, Phan, See-Chun, Merchant, Mark, Hsu, Jessie, Yu, Wei, Xia, Qi, Koralek, Daniel, Luhn, Patricia, Aldairy, Wassim
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Public Library of Science 2015
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4596876/
https://ncbi.nlm.nih.gov/pubmed/26445503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0139679
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items